DeepMed Research

Crimson BioPharm, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)

Phase 1

Not yet recruiting

Conditions: Glioblastoma

Interventions: Drug: CM93

First Posted Date: 2021-06-21

Last Posted Date: 2024-08-21

Lead Sponsor: Crimson Biopharm Inc.

Target Recruit Count: 72

Registration Number: NCT04933422

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy